Skip to main content

Table 3 Adverse events reported by ≥5% of patients (N = 122)

From: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

Adverse event

n (%)

Patients with any TEAE

83 (68.0)

Nausea

26 (21.3)

Headache

11 (9.0)

Anxiety

8 (6.6)

Constipation

7 (5.7)

Diarrhea

7 (5.7)

  1. TEAE treatment-emergent adverse event